Gene therapies offer the promise of a one-and-done treatment for debilitating chronic disease—but payers still have lots of questions—from patient selection to duration of response. In this Clinical Leader article, Jeremy Schafer, PharmD, MBA, Senior Vice President of specialty solutions at Precision for Value, describes how well-designed clinical trials can answer these questions.

To read the full article, click here